The ATR inhibitor overcomes fork stabilization in BRCA-deficient cells by preventing RAD51 loading onto stalled forks and triggering MRE11-mediated fork degradation, as shown in PARP-resistant ovarian cancer cells and PDXs (Yazinski et al. 2017). This evidence concerns the gene ATR and ovarian cancer.